Welcome to our dedicated page for Uniqure news (Ticker: QURE), a resource for investors and traders seeking the latest updates and insights on Uniqure stock.
uniQure (QURE) is a leading biotechnology company advancing innovative gene therapies for severe genetic diseases, including hemophilia and Huntington's disease. This dedicated news hub provides investors and stakeholders with timely updates on clinical developments, regulatory milestones, and strategic partnerships.
Access the most comprehensive collection of official press releases, clinical trial progress reports, and financial disclosures directly impacting QURE's trajectory. Our curated feed ensures you never miss critical updates about therapeutic advancements or collaborative ventures with industry leaders like Bristol Myers Squibb.
This resource serves investors seeking material events analysis, researchers tracking gene therapy innovations, and healthcare professionals monitoring treatment breakthroughs. All content is sourced from verified channels to maintain accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to uniQure's latest announcements. Check back regularly for real-time updates on one of biotech's most dynamic gene therapy innovators.
uniQure N.V. (NASDAQ: QURE) announced the granting of equity awards to 31 employees to incentivize their employment, as per Nasdaq Listing Rule 5635(c)(4). The awards include 63,300 restricted share units (RSUs) and options for 57,500 ordinary shares, with an exercise price of $20.06, reflecting the closing price on the grant date of February 23, 2023. Options will vest over four years, with one-quarter vesting after the first year and the remainder in quarterly installments. RSUs will vest over three years. This initiative is part of uniQure's strategy to attract talent as it advances its gene therapy pipeline targeting severe diseases.
uniQure N.V. (NASDAQ: QURE) announced its participation in various investor and scientific conferences in March 2023. Key events include the Cowen Annual Healthcare Conference from March 6-8 in Boston, where CEO Matt Kapusta will engage in one-on-one meetings and a panel discussion.
Other conferences include the Bioprocessing Summit Europe on March 15 in Barcelona, the Huntington's Disease Youth Organization Congress from March 17-19 in Glasgow, and the MDA Conference from March 19-22 in Austin. The company aims to showcase its advancements in gene therapy, particularly for severe medical conditions like hemophilia B.
uniQure N.V. (NASDAQ: QURE) announced significant milestones, including U.S. and European marketing approvals for HEMGENIX®, the first gene therapy for hemophilia B. The company is advancing AMT-130 for Huntington’s disease, with updates expected in Q2 2023. Plans for new clinical trials for AMT-260 (temporal lobe epilepsy) and AMT-162 (SOD1 ALS) are set for the second half of 2023. Financial results show a revenue decline to $106.5 million in 2022, down from $524 million in 2021, with a net loss of $126.8 million. The company holds $392.8 million in cash, expected to fund operations into 2025, contingent on milestone payments for HEMGENIX®.
uniQure (NASDAQ: QURE) announced significant results from the pivotal HOPE-B clinical study of its gene therapy HEMGENIX® for hemophilia B, published in the New England Journal of Medicine. The study demonstrated HEMGENIX® significantly reduced the annualized bleeding rate (ABR) by 71% for spontaneous bleeds and 78% for joint bleeds. After treatment, 96.3% of patients discontinued factor IX prophylaxis. The therapy maintains elevated factor IX levels over 18 months without serious adverse events related to treatment reported. HEMGENIX® is approved in the U.S. and EU, representing a transformative development for hemophilia B patients.
FAQ
What is the current stock price of Uniqure (QURE)?
What is the market cap of Uniqure (QURE)?
